Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint

HIGHLIGHTS

• who: Zewei Zhang from the Department of Radiation Oncology, Sun Yat-Sen University Center, Guangzhou, China have published the article: Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinomau2014an exploration of surrogate endpoint, in the Journal: (JOURNAL)
• what: The authors aimed to examine if PFS could function as an OS surrogate in advanced Esophageal Squamous Cell Carcinoma (ESCC) treated with first-line immunochemotherapy. The authors evaluated the PFS-OS correlation in a retrospective cohort of patients, and a widely-accepted meta-analytic two-stage validation . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.